Citrate serves multiple vital functions in cells, acting primarily as an intermediary in the citric acid cycle, a foundational metabolic pathway responsible for generating energy in the form of ATP. Beyond energy production, citrate contributes to biosynthetic processes essential for cell growth and maintenance. Notably, in neurons, citrate also functions as a neuromodulator, influencing synaptic activity. This dual role heightens the necessity for precise regulation of citrate uptake in the brain, a task mediated predominantly by the SLC13A5 transporter situated in the neuronal cell membranes.

The SLC13A5 protein belongs to a family of solute carrier (SLC) transporters that facilitate the translocation of various substrates across cellular membranes, playing critical roles in maintaining cellular homeostasis. In the brain, high levels of SLC13A5 expression ensure adequate citrate influx from the cerebrospinal fluid into neurons. When mutations impair this transporter’s function, citrate levels become dysregulated, which has been directly linked to the onset of DEE, a condition characterized by early-life seizures and neurodevelopmental impairment.

Despite the clinical significance, the molecular mechanisms governing how distinct SLC13A5 mutations lead to disease phenotypes were poorly understood until now. To address this, the CeMM team employed an advanced technique called deep mutational scanning (DMS), enabling the systematic evaluation of almost ten thousand possible genetic variants of SLC13A5 for their functional impact. This unprecedented scale of analysis allowed for the identification of critical mutations affecting transporter stability, cellular localization, and citrate uptake efficiency.

From this massive dataset, 38 mutant variants were further subjected to experimental interrogation to validate computational predictions and to dissect the biophysical alterations caused by these mutations. This integrative approach revealed that certain mutations lead to reduced protein expression at the membrane, while others compromise the transport kinetics of citrate, decreasing its cellular availability. Such molecular impairments collectively result in defective metabolic processes in neurons, thereby underpinning the pathological basis of SLC13A5 transporter disorder.

Moreover, the researchers introduced a novel framework to assess protein stability across distinct conformational states of SLC13A5, coupled with evolutionary conservation scoring to prioritize variants with probable pathogenicity. These innovative computational tools serve not only in characterizing rare disease mutations but also in expanding our understanding of population-level genetic diversity and its subtle impacts on protein function.

The implications of these findings extend far beyond the narrow confines of a single rare disease. Understanding how membrane transporters like SLC13A5 operate and fail at a molecular level provides essential insights into neuronal biochemistry and paves the way for rational drug design. Precision medicine approaches can now leverage this data to better diagnose and potentially develop targeted therapies for individuals afflicted by SLC13A5-associated epileptic encephalopathy.

“Systematic functional characterization of genetic variants is a powerful strategy, particularly to elucidate the molecular underpinnings of rare and complex human diseases,” notes co-first author Wen-An Wang. His colleague Evandro Ferrada adds that combining experimental data with computational modeling bridges the gap between genotype and phenotype, offering a comprehensive picture of variant effects that can inform clinical interpretation.

This work was made possible through synergy with the RESOLUTE and REsolution consortia, multi-institutional efforts geared towards decoding the entire family of SLC transporters and understanding their roles in cellular logistics. Patient-derived data, obtained from the TESS Research Foundation, further grounded the molecular findings within a clinical context aligned with patient needs.

Giulio Superti-Furga, senior author and scientific director at CeMM, emphasizes that this study exemplifies how blending large-scale mutational analysis with structural and functional elucidation can dramatically enhance our grasp of transporter biology. It underscores the broader principle that precision functional mapping of membrane proteins is essential for translating genetic variation into mechanistic insights and clinical solutions.

As the SLC13A5 transporter’s malfunction is implicated not only in epilepsy but might also be linked indirectly to other neurological and metabolic disorders, future investigations building on this work could unlock new therapeutic avenues. The potential to modulate transporter activity pharmacologically or through gene therapy offers hope for conditions that currently have no effective treatments.

In conclusion, this landmark study sets a high bar for variant effect mapping in membrane proteins and establishes a foundational knowledge base for rare disease research. By integrating deep mutational scans with computational and biochemical methodologies, the investigators have not only clarified the pathogenesis of SLC13A5 Citrate Transporter Disorder but have also broadened the horizon for understanding metabolic control in neuronal health and disease.

Subject of Research: Cells

Article Title: Large-scale experimental assessment of variant effects on the structure and function of the citrate transporter SLC13A5

News Publication Date: 27-Jun-2025

Web References:
10.1126/sciadv.adx3011

References:
Wang, W.-A., Ferrada, E., Klimek, C., Osthushenrich, T., MacNamara, A., Wiedmer, T., & Superti-Furga, G. (2025). Large-scale experimental assessment of variant effects on the structure and function of the citrate transporter SLC13A5. Science Advances, 11(26), eadx3011.

Image Credits:
© CeMM / © Franzi Kreis/CeMM

Keywords: Transporter proteins, Transmembrane proteins, Biomolecules, Life sciences, Cell biology

For decades, neuroscience textbooks have perpetuated the notion that neuromodulators like norepinephrine fine-tune neural circuits through direct action on neurons, the electrically excitable cells responsible for fast synaptic transmission. Yet, the WashU Medicine team, led by Dr. Thomas Papouin, employed an array of sophisticated experimental techniques, including selective stimulation of norepinephrine secretion in murine models and acute brain slice methodologies, to reveal a more intricate interaction. These experiments demonstrated that while norepinephrine does modulate neuronal synapses, the presence and activity of astrocytes are essential mediators of this effect, underscoring a pivotal paradigm shift.

Astrocytes, characterized by their star-shaped, highly ramified processes, have traditionally been considered passive support cells. However, over the past three decades, accumulating evidence has suggested that astrocytes intimately associate with synapses, modulating neurotransmission and synaptic plasticity. Their unique morphology permits them to envelop numerous synapses, positioning them to monitor the extracellular milieu and respond dynamically to neurochemical signals. This recent study extends that knowledge by establishing a direct causal link between norepinephrine’s neuromodulatory capacity and astrocyte-mediated signaling cascades.

Experimental findings revealed that norepinephrine triggers astrocytic activation, which in turn leads to the release of a secondary chemical messenger that effectively dampens synaptic transmission. Importantly, when the ability of neurons to directly sense norepinephrine was experimentally abrogated, the modulation of synapses persisted, reinforcing the notion that astrocytes are the principal conduits for norepinephrine’s modulatory actions. Conversely, silencing astrocytic responsiveness to norepinephrine abolished these effects, thereby highlighting the necessity of astrocyte-neuromodulator interactions in the regulation of synaptic efficacy.

This astrocyte-dependent neuromodulation occurs over slower timescales compared to direct neuronal signaling, suggesting a complex, multi-temporal orchestration of brain activity that has been underappreciated until now. Such temporal dynamics may underpin processes requiring sustained attention and cognitive flexibility, functions traditionally attributed to fast neurotransmitter systems. The implications for neuropsychiatric disorders are profound, particularly considering that many cognitive dysfunctions reflect aberrations in neuromodulatory systems.

Dr. Papouin and his group propose that astrocytes, far from being mere bystanders, are active architects in the remodeling of brain networks during states of heightened vigilance and attention. This astrocytic involvement could explain some of the subtleties and resilience observed in synaptic plasticity, especially under conditions where neuromodulatory tone fluctuates. By elucidating this mechanism, the research provides a vital framework for revisiting therapeutic strategies aimed at enhancing cognitive function or ameliorating attentional deficits.

In light of these findings, the researchers have embarked on investigative efforts to reassess the mechanisms of existing pharmaceuticals that target norepinephrine signaling, commonly prescribed for conditions such as attention deficit hyperactivity disorder (ADHD) and depression. It remains an open question whether the efficacy of these drugs is contingent upon astrocytic functions. If so, designing treatments that directly harness astrocyte biology could herald a new class of interventions with potentially improved efficacy and specificity.

Furthermore, this study highlights the broader neuroscientific importance of glial cells in brain health and disease. Whereas neurons have historically dominated research focus, astrocytes and other glial cells are increasingly recognized for their crucial roles in maintaining homeostasis, modulating synaptic function, and shaping neural circuits. This shift towards glia-centric neuroscience may unravel previously unexplained facets of brain complexity and neuropathology.

Critically, the experimental design implemented by the WashU team combined optogenetics, calcium imaging, and pharmacological manipulation to parse the sequence of events from norepinephrine release to synaptic modulation. Observations that astrocyte activation precedes synaptic dampening indicate a direct signaling pathway, challenging earlier models that posited a direct neuron-to-neuron neuromodulatory route. These technical advancements solidify the robustness of their conclusions.

The translational potential of harnessing astrocyte-mediated pathways extends beyond cognitive disorders, possibly influencing strategies for memory enhancement and emotional regulation. Because astrocytes can integrate diverse neurotransmitter signals and modulate synaptic outputs accordingly, targeted modulation of their activity represents a frontier in neurotherapeutics that could complement or supersede existing neuron-focused treatments.

In sum, the discovery that norepinephrine operates through astrocytes to govern synaptic dynamics compels a reevaluation of brain function dogma. It underscores the complexity of neurochemical interactions and the essential role of glial cells in orchestrating neural networks. This insight not only propels forward the scientific understanding of brain circuitry but also sets the stage for innovative approaches to neurological and psychiatric care, transforming astrocytes from passive bystanders into active protagonists of brain health.

Subject of Research: Animal tissue samples

Article Title: Norepinephrine signals through astrocytes to modulate synapses

News Publication Date: 15-May-2025

Web References: https://www.science.org/doi/full/10.1126/science.adq5480

References: Lefton KB, Wu Y, Dai Y, Okuda T, Zhang Y, Yen A, Rurak GM, Walsh S, Manno R, Myagmar B-E, Dougherty JD, Samineni VK, Simpson PC, Papouin T. Norepinephrine signals through astrocytes to modulate synapses. Science. May 15, 2025. DOI: 10.1126/science.adq5480

Image Credits: IMAGE COURTESY YIFAN WU

Keywords: Neuroscience, Astrocytes, Neuronal synapses